Drug Industry Dodges Its Worst Fears in Trump’s Plan to Lower Prices
- ‘American Patients First’ proposals could remake supply chain
- Pharma stocks, PBMs rise after remarks despite harsh language
This article is for subscribers only.
President Donald Trump’s plan to lower U.S. drug prices avoids some of the harshest steps that the pharmaceutical industry and the network of companies that distribute its products feared.
Calling his proposal the most sweeping attempt in U.S. history to lower drug prices, Trump wants to increase competition for medicines, cut list prices and reduce patients’ out-of-pocket costs. Yet it also preserves -- and in some cases expands -- the role of the pharmacy middlemen the administration has blamed for many problems with drug costs.